Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 4Prostatic Neoplasms 3Carcinoma, Hepatocellular 3Pain, Postoperative 2Lung Neoplasms 2Inflammation 2Stomach Neoplasms 1Postoperative Nausea and Vomiting 1Pancreatic Neoplasms 1Neuroma, Acoustic 1Neoplasms 1Melanoma 1Liver Neoplasms 1Liver Diseases 1Gynecological Laparoscopic Surgery 1Esophageal Neoplasms 1Emergence Delirium 1Chronic Pain 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × Sufentanil × Clear all
NCT00943566 2015-09-15

A Safety and Efficacy Study of Sufentanil Transdermal System in Patients With Chronic Pain Due to Cancer

Labtec GmbH

Phase 2 Withdrawn

Neoplasms, Pain, Chronic Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡